1. Phylogeny  
   Cyclin-dependent kinase 6 (CDK6) is a member of the serine/threonine kinase family that evolved early among eukaryotes and is classified within the group of cell cycle–regulating CDKs. Phylogenetically, CDK6 is closely related to CDK4, and together they share unique features that distinguish them from other cell cycle kinases such as CDK2. Both CDK6 and CDK4 exhibit a high degree of sequence conservation in the catalytic domain and are evolutionarily conserved across mammalian species, reflecting their critical roles in cell cycle control. In addition, although CDK6 diverged from other CDKs at an early stage, it retains a conserved kinase fold with an N-terminal lobe rich in β-sheets and a larger C-terminal lobe (as seen in structural studies and comparative analyses) (asghar2015thehistoryand pages 1-2, korolchuk2018structuralandfunctional pages 31-35). Orthologs of CDK6 have been identified in several metazoans, and genetic studies in mice have confirmed that CDK6 plays nonredundant roles in processes such as thymocyte development and neurogenesis, underscoring its conserved function in diverse cell types (tigan2016cdk6—areviewof pages 1-2, hallett2017structuralandfunctional pages 27-30).
2. Reaction Catalyzed  
   CDK6 catalyzes the transfer of a phosphate group from ATP to specific serine or threonine residues on substrate proteins. The canonical reaction involves ATP and a protein substrate containing an accessible serine/threonine residue to yield ADP and the phosphorylated protein. Physiologically, CDK6 phosphorylates targets such as the retinoblastoma protein (pRB/RB1) and nucleophosmin (NPM1), which results in conformational and functional changes critical for the regulation of cell cycle progression from the G1 to S phase. This phosphorylation leads to the inactivation of pRB, liberating E2F transcription factors that promote the transcription of genes essential for DNA synthesis and progression through the cell cycle (asghar2015thehistoryand pages 9-10, tadesse2015targetingcdk6in pages 35-38).
3. Cofactor Requirements  
   The catalytic activity of CDK6 depends primarily on ATP, which serves as the phosphate donor in its phosphorylation reaction. Like many serine/threonine protein kinases, CDK6 also requires the presence of divalent metal ions, typically Mg²⁺, to coordinate ATP binding and stabilize the transition state during catalysis. These cofactors are essential for proper substrate orientation and for the efficient transfer of the phosphoryl group (korolchuk2018structuralandfunctional pages 168-171, tadesse2018cyclindependentkinase2 pages 4-8).
4. Substrate Specificity  
   CDK6 exhibits substrate specificity characteristic of cell cycle kinases, with a strong preference for phosphorylating serine/threonine residues within particular sequence contexts. Its best-characterized substrate is the retinoblastoma protein (pRB), where phosphorylation at multiple sites is critical for the release of E2F transcription factors and subsequent cell cycle progression. In addition to pRB, CDK6 phosphorylates NPM1 and has been reported to modulate the activity of other cell cycle regulatory proteins. Although an exact consensus motif for CDK6 is not uniformly defined across all studies, the structural and biochemical analyses indicate that substrate recognition involves a complementary binding interface formed by the catalytic domain and the associated D-type cyclins, which facilitate precise substrate docking (asghar2015thehistoryand pages 4-5, tadesse2015targetingcdk6in pages 6-9, wood2018structuralinsightsinto pages 10-11).
5. Structure  
   CDK6 is a 326-amino-acid serine/threonine kinase consisting primarily of a conserved kinase domain that is organized into a bilobal structure. The N-terminal lobe of CDK6 contains several antiparallel β-sheets and a key α-helix that is critical for cyclin binding, while the larger C-terminal lobe is predominantly composed of α-helices and houses the activation loop (T-loop) along with the substrate-binding and ATP-binding sites. Essential structural elements include the glycine-rich P-loop, which is responsible for anchoring the phosphates of ATP, and conserved motifs such as the catalytic loop and DFG motif, which ensure proper alignment of catalytic residues. Upon binding to D-type cyclins (such as cyclin D1, D2, or D3), CDK6 undergoes a conformational rearrangement that positions the αC-helix in an “in” conformation, thereby allowing critical interactions between the kinase and its substrates. Additionally, interaction with cyclins not only activates the kinase but also contributes to substrate specificity by providing complementary contact surfaces. High-resolution structures and crystallographic studies, including those demonstrating the CDK6 complexes with cyclin D and inhibitors (e.g., the structural insights from INK4 inhibitor studies), further highlight unique aspects of CDK6 regulation and activation (hallett2017structuralandfunctional pages 223-226, tadesse2015targetingcdk6in pages 9-13, wood2018structuralinsightsinto pages 14-15).
6. Regulation  
   The activity of CDK6 is tightly regulated by multiple mechanisms. A primary mode of regulation involves its association with D-type cyclins (D1, D2, D3) during the G1 phase of the cell cycle, which is necessary for its activation and for proper substrate orientation. In addition, CDK6 is regulated by CDK inhibitory proteins (CKIs), notably those in the INK4 family (such as p16^INK4A and p19^INK4D) that bind to monomeric CDK6 or the CDK6–cyclin complexes to inhibit kinase activity. Members of the Cip/Kip family (e.g., p21^Cip1 and p27^Kip1) also interact with CDK6–cyclin complexes; interestingly, these proteins can have dual roles by sometimes facilitating complex assembly and nuclear localization, while in other contexts inhibiting catalytic activity. Furthermore, phosphorylation plays a critical role in CDK6 regulation. Phosphorylation of residues within the T-loop by the CDK-activating kinase (CAK) is necessary to achieve full kinase activity, while inhibitory phosphorylation events mediated by kinases such as Wee1 or Myt1 can reduce CDK6’s activity. Chaperone systems involving proteins such as Hsp90 and Cdc37 have also been shown to assist in the correct folding, stabilization, and maturation of CDK6, ensuring that only appropriately assembled kinase complexes are active (tadesse2015targetingcdk6in pages 13-16, tigan2016cdk6—areviewof pages 2-3, korolchuk2018structuralandfunctional pages 26-31).
7. Function  
   CDK6 is a critical regulator of cell cycle progression, predominantly controlling the transition from the G1 phase to the S phase. Its canonical function is to phosphorylate key substrates such as pRB, leading to the release of E2F transcription factors that actively promote the transcription of genes required for DNA replication and cell cycle progression. Beyond its central role in cell cycle control, CDK6 is involved in regulating cell differentiation; it plays a dual role by both supporting cell proliferation in certain lineages (for example, erythroid and hematopoietic cells) and promoting cell cycle exit during differentiation in other contexts. In the developing central nervous system, CDK6 is essential within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles, where it promotes the production of newborn neurons by modulating the duration of the G1 phase. CDK6 is also important during thymocyte development and in regulating myeloid progenitor proliferation. Intriguingly, CDK6 possesses kinase-independent functions as well; in astrocytes, for example, it modulates the actin cytoskeleton, leading to loss of stress fibers and enhanced motility during differentiation. Additionally, in the context of myeloid cells, CDK6 prevents differentiation by interfering with the transcriptional activator RUNX1, thereby maintaining a proliferative state. This multifunctionality underscores the pivotal role of CDK6 not only in cell cycle progression but also in lineage commitment, morphogenesis, and potentially in cellular senescence delays (asghar2015thehistoryand pages 15-16, giovanni2016investigationaldrugstargeting pages 34-38, tigan2016cdk6—areviewof pages 7-8).
8. Other Comments  
   CDK6 is a validated target in oncology due to its essential role in driving cell proliferation and its frequent dysregulation in cancer. Several selective inhibitors have been developed that target the ATP-binding pocket of CDK6, and many of these agents – including Palbociclib, Ribociclib, and Abemaciclib – are currently in clinical use or undergoing trials for the treatment of hormone receptor–positive breast cancer and other malignancies. In addition to its kinase-dependent activity, the transcriptional regulatory functions of CDK6 have spurred investigations into novel therapeutic strategies aimed at disrupting both its catalytic and scaffolding roles. While mutations in CDK6 itself appear less common than alterations in its regulatory partners (such as p16^INK4A), overexpression and aberrant activation of CDK6 are well documented in various cancers, including lymphoid neoplasms and gliomas. The intricate balance between cyclin binding, CKI interactions, and post-translational modifications remains an active area of research, with new insights regularly emerging on how best to modulate CDK6 activity for therapeutic benefit (goel2022targetingcdk4and pages 1-3, tadesse2015targetingcdk6in pages 16-20, wood2018structuralinsightsinto pages 19-20, hallett2017structuralandfunctional pages 38-42).
9. References  
   OpenTargets Search: -CDK6; asghar2015thehistoryand pages 1-2; asghar2015thehistoryand pages 4-5; asghar2015thehistoryand pages 9-10; asghar2015thehistoryand pages 15-16; giovanni2016investigationaldrugstargeting pages 1-6; giovanni2016investigationaldrugstargeting pages 29-34; giovanni2016investigationaldrugstargeting pages 34-38; giovanni2016investigationaldrugstargeting pages 6-10; goel2022targetingcdk4and pages 1-3; hallett2017structuralandfunctional pages 223-226; hallett2017structuralandfunctional pages 27-30; hallett2017structuralandfunctional pages 30-34; hallett2017structuralandfunctional pages 38-42; korolchuk2018structuralandfunctional pages 168-171; korolchuk2018structuralandfunctional pages 23-26; korolchuk2018structuralandfunctional pages 26-31; korolchuk2018structuralandfunctional pages 31-35; tadesse2015targetingcdk6in pages 1-6; tadesse2015targetingcdk6in pages 13-16; tadesse2015targetingcdk6in pages 16-20; tadesse2015targetingcdk6in pages 20-24; tadesse2015targetingcdk6in pages 35-38; tadesse2015targetingcdk6in pages 6-9; tadesse2015targetingcdk6in pages 9-13; tadesse2018cyclindependentkinase2 pages 4-8; tigan2016cdk6—areviewof pages 1-2; tigan2016cdk6—areviewof pages 2-3; tigan2016cdk6—areviewof pages 3-4; tigan2016cdk6—areviewof pages 6-6; tigan2016cdk6—areviewof pages 6-7; tigan2016cdk6—areviewof pages 7-8; tigan2016cdk6—areviewof pages 4-5; tigan2016cdk6—areviewof pages 5-6; wang2017themetabolicfunction pages 1-3; wood2018structuralinsightsinto pages 1-2; wood2018structuralinsightsinto pages 10-11; wood2018structuralinsightsinto pages 14-15; wood2018structuralinsightsinto pages 18-19; wood2018structuralinsightsinto pages 19-20.

References

1. (OpenTargets Search: -CDK6): Open Targets Query (-CDK6, 24 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.
2. (asghar2015thehistoryand pages 4-5): Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, and Erik S. Knudsen. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery, 14:130-146, Jan 2015. URL: https://doi.org/10.1038/nrd4504, doi:10.1038/nrd4504. This article has 1885 citations and is from a highest quality peer-reviewed journal.
3. (giovanni2016investigationaldrugstargeting pages 1-6): Carmen Di Giovanni, Ettore Novellino, Adriana Chilin, Antonio Lavecchia, and Giovanni Marzaro. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 25:1215-1230, Sep 2016. URL: https://doi.org/10.1080/13543784.2016.1234603, doi:10.1080/13543784.2016.1234603. This article has 31 citations and is from a peer-reviewed journal.
4. (giovanni2016investigationaldrugstargeting pages 29-34): Carmen Di Giovanni, Ettore Novellino, Adriana Chilin, Antonio Lavecchia, and Giovanni Marzaro. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 25:1215-1230, Sep 2016. URL: https://doi.org/10.1080/13543784.2016.1234603, doi:10.1080/13543784.2016.1234603. This article has 31 citations and is from a peer-reviewed journal.
5. (giovanni2016investigationaldrugstargeting pages 34-38): Carmen Di Giovanni, Ettore Novellino, Adriana Chilin, Antonio Lavecchia, and Giovanni Marzaro. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 25:1215-1230, Sep 2016. URL: https://doi.org/10.1080/13543784.2016.1234603, doi:10.1080/13543784.2016.1234603. This article has 31 citations and is from a peer-reviewed journal.
6. (giovanni2016investigationaldrugstargeting pages 6-10): Carmen Di Giovanni, Ettore Novellino, Adriana Chilin, Antonio Lavecchia, and Giovanni Marzaro. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 25:1215-1230, Sep 2016. URL: https://doi.org/10.1080/13543784.2016.1234603, doi:10.1080/13543784.2016.1234603. This article has 31 citations and is from a peer-reviewed journal.
7. (goel2022targetingcdk4and pages 1-3): Shom Goel, Johann S. Bergholz, and Jean J. Zhao. Targeting cdk4 and cdk6 in cancer. Nature Reviews Cancer, 22:356-372, Mar 2022. URL: https://doi.org/10.1038/s41568-022-00456-3, doi:10.1038/s41568-022-00456-3. This article has 360 citations and is from a domain leading peer-reviewed journal.
8. (hallett2017structuralandfunctional pages 223-226): ST Hallett. Structural and functional characterisation of cyclin-dependent kinase 6-cyclin d complexes. Unknown journal, 2017.
9. (hallett2017structuralandfunctional pages 30-34): ST Hallett. Structural and functional characterisation of cyclin-dependent kinase 6-cyclin d complexes. Unknown journal, 2017.
10. (hallett2017structuralandfunctional pages 38-42): ST Hallett. Structural and functional characterisation of cyclin-dependent kinase 6-cyclin d complexes. Unknown journal, 2017.
11. (korolchuk2018structuralandfunctional pages 168-171): SM Korolchuk. Structural and functional characterisation of cyclin dependent kinase 1 containing complexes. Unknown journal, 2018.
12. (tadesse2015targetingcdk6in pages 1-6): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
13. (tadesse2015targetingcdk6in pages 13-16): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
14. (tadesse2015targetingcdk6in pages 16-20): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
15. (tadesse2015targetingcdk6in pages 20-24): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
16. (tadesse2015targetingcdk6in pages 6-9): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
17. (tadesse2015targetingcdk6in pages 9-13): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
18. (tigan2016cdk6—areviewof pages 1-2): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
19. (tigan2016cdk6—areviewof pages 2-3): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
20. (tigan2016cdk6—areviewof pages 3-4): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
21. (tigan2016cdk6—areviewof pages 6-6): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
22. (tigan2016cdk6—areviewof pages 6-7): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
23. (tigan2016cdk6—areviewof pages 7-8): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
24. (asghar2015thehistoryand pages 1-2): Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, and Erik S. Knudsen. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery, 14:130-146, Jan 2015. URL: https://doi.org/10.1038/nrd4504, doi:10.1038/nrd4504. This article has 1885 citations and is from a highest quality peer-reviewed journal.
25. (asghar2015thehistoryand pages 15-16): Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, and Erik S. Knudsen. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery, 14:130-146, Jan 2015. URL: https://doi.org/10.1038/nrd4504, doi:10.1038/nrd4504. This article has 1885 citations and is from a highest quality peer-reviewed journal.
26. (asghar2015thehistoryand pages 9-10): Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, and Erik S. Knudsen. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery, 14:130-146, Jan 2015. URL: https://doi.org/10.1038/nrd4504, doi:10.1038/nrd4504. This article has 1885 citations and is from a highest quality peer-reviewed journal.
27. (hallett2017structuralandfunctional pages 27-30): ST Hallett. Structural and functional characterisation of cyclin-dependent kinase 6-cyclin d complexes. Unknown journal, 2017.
28. (korolchuk2018structuralandfunctional pages 23-26): SM Korolchuk. Structural and functional characterisation of cyclin dependent kinase 1 containing complexes. Unknown journal, 2018.
29. (korolchuk2018structuralandfunctional pages 26-31): SM Korolchuk. Structural and functional characterisation of cyclin dependent kinase 1 containing complexes. Unknown journal, 2018.
30. (korolchuk2018structuralandfunctional pages 31-35): SM Korolchuk. Structural and functional characterisation of cyclin dependent kinase 1 containing complexes. Unknown journal, 2018.
31. (tadesse2015targetingcdk6in pages 35-38): Solomon Tadesse, Mingfeng Yu, Malika Kumarasiri, Bich Thuy Le, and Shudong Wang. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle, 14:3220-3230, Oct 2015. URL: https://doi.org/10.1080/15384101.2015.1084445, doi:10.1080/15384101.2015.1084445. This article has 174 citations and is from a peer-reviewed journal.
32. (tadesse2018cyclindependentkinase2 pages 4-8): Solomon Tadesse, Elizabeth C. Caldon, Wayne Tilley, and Shudong Wang. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. Journal of Medicinal Chemistry, 62:4233-4251, Dec 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b01469, doi:10.1021/acs.jmedchem.8b01469. This article has 247 citations and is from a highest quality peer-reviewed journal.
33. (tigan2016cdk6—areviewof pages 4-5): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
34. (tigan2016cdk6—areviewof pages 5-6): A-S Tigan, F Bellutti, K Kollmann, G Tebb, and V Sexl. Cdk6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 35:3083-3091, Oct 2016. URL: https://doi.org/10.1038/onc.2015.407, doi:10.1038/onc.2015.407. This article has 173 citations and is from a domain leading peer-reviewed journal.
35. (wang2017themetabolicfunction pages 1-3): Haizhen Wang, Brandon N. Nicolay, Joel M. Chick, Xueliang Gao, Yan Geng, Hong Ren, Hui Gao, Guizhi Yang, Juliet A. Williams, Jan M. Suski, Mark A. Keibler, Ewa Sicinska, Ulrike Gerdemann, W. Nicholas Haining, Thomas M. Roberts, Kornelia Polyak, Steven P. Gygi, Nicholas J. Dyson, and Piotr Sicinski. The metabolic function of cyclin d3–cdk6 kinase in cancer cell survival. Nature, 546:426-430, Jun 2017. URL: https://doi.org/10.1038/nature22797, doi:10.1038/nature22797. This article has 356 citations and is from a highest quality peer-reviewed journal.
36. (wood2018structuralinsightsinto pages 1-2): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
37. (wood2018structuralinsightsinto pages 10-11): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
38. (wood2018structuralinsightsinto pages 14-15): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
39. (wood2018structuralinsightsinto pages 18-19): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.
40. (wood2018structuralinsightsinto pages 19-20): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 264 citations and is from a peer-reviewed journal.